Bloomberg Intelligence AMD Suffers Worst Rout Since 2018 on Disappointing Forecast
Feb 4, 2026
Kunjan Sobhani, semiconductor analyst focused on GPUs and China export rules. Woo Jin-ho, hardware analyst tracking AI servers and DRAM trends. Sam Fazeli, pharma analyst covering Lilly and GLP-1s. Jody Lurie, credit analyst on restaurants, cruises, and franchise models. They discuss AMD’s forecast-led sell-off and GPU demand, China export licenses, Supermicro’s AI server strength, DRAM price effects, Lilly’s guidance, and Yum and Disney developments.
AI Snips
Chapters
Transcript
Episode notes
Lilly Gaining Volume Amid Price Pressure
- Eli Lilly projects volume growth despite price pressure and appears to outperform Novo in sustained weight-loss demand.
- Sam Fazeli attributes Lilly's edge to clinical results and expects volume gains to offset price declines in 2026.
Don't Count On Illegal Copycat Injectables
- Avoid relying on illegitimate compounding or copycat telehealth injections; these practices remain legally risky.
- Sam Fazeli warns patents protect these drugs and unauthorized compounding should not be a durable market threat.
Multi-Dose Pen Adds Margin And Sustainability
- Multi-dose pen approval for ZipBound improves sustainability and may raise margins by reducing disposable pen waste.
- Sam says proper storage remains important but the device benefits both patients and manufacturers.